Microbiotica, a clinical-stage biopharma company, has announced the dosing of the first patient in its Phase 1b First-in-Human trial, COMPOSER-1, for MB310 in ulcerative colitis ( ...

Arcellx Inc, a biotechnology firm focused on cell therapy innovations, has announced impressive results from its studies on ...

Elsevier, a leader in information and analytics, has announced its support for The Pistoia Alliance in promoting safe and responsible AI adoption in drug discovery. This effort aims to address key AI ...

Johnson & Johnson has announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved BALVERSA (erdafitinib) for treating adults with unresectable or metastatic ...

When I first entered the clinical research industry more than 20 years ago, trials were focused mainly on recruitment goals and data collection, with less attention to the challenges faced by research ...

Dundee-based Ubiquigent Limited and San Francisco’s Alleo Labs Corp have entered a strategic partnership to advance deubiquitinase (DUB)-focused drug discovery using AI. The collaboration aims to ...

Alexion, AstraZeneca Rare Disease, announced that the National Institute for Health and Care Excellence (NICE) has given a positive recommendation for Voydeya (danicopan). This first-in-class, oral ...

Valneva Scotland has partnered with Team Jak, a West Lothian-headquartered charity focused on supporting children and young people with cancer. The Livingston-based vaccine producer will provide ...

The London hub is home to life sciences companies including Novartis, Engitix and invoX Pharma Vivan Therapeutics has signed a new five-year lease at White City Place, a biotech hub in London home to ...

New treatment option for patients with newly diagnosed multiple myeloma The European Commission has approved the subcutaneous (SC) formulation of DARZALEX (daratumumab) in combination with bortezomib, ...

There are around 55,100 new prostate cancer cases in the UK every year HBC Immunology (HBCI) has announced that an oral formulation of its lead peptide “significantly augmented” the anti-tumour ...